Loading clinical trials...
Loading clinical trials...
Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Fluconazole (Hard Capsule) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)
Conditions
Interventions
BI 1744
Fluconazole
Locations
1
Germany
1222.48.1 Boehringer Ingelheim Investigational Site
Berlin, Germany
Start Date
May 1, 2010
Primary Completion Date
July 1, 2010
Last Updated
June 10, 2014
NCT06716502
NCT00090662
NCT06290258
NCT07310264
NCT07483606
NCT07310901
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions